BRPI0607499A2 - combinação antitumor que compreende derivados de distamicina acriloìla substituìda e anticorpos que inibem fatores de crescimento ou seus receptores - Google Patents
combinação antitumor que compreende derivados de distamicina acriloìla substituìda e anticorpos que inibem fatores de crescimento ou seus receptoresInfo
- Publication number
- BRPI0607499A2 BRPI0607499A2 BRPI0607499-5A BRPI0607499A BRPI0607499A2 BR PI0607499 A2 BRPI0607499 A2 BR PI0607499A2 BR PI0607499 A BRPI0607499 A BR PI0607499A BR PI0607499 A2 BRPI0607499 A2 BR PI0607499A2
- Authority
- BR
- Brazil
- Prior art keywords
- receptors
- antibodies
- distamycin derivatives
- growth factors
- inhibit growth
- Prior art date
Links
- -1 acrylamide distamycin derivatives Chemical class 0.000 title abstract 3
- 239000003102 growth factor Substances 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 206010027476 Metastases Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
Abstract
COMBINAçãO ANTITUMOR QUE COMPREENDE DERIVADOS DE DISTAMICINA ACRILOìLA SUBSTITUìDA E ANTICORPOS QUE INIBEM FATORES DE CRESCIMENTO OU SEUS RECEPTORES. A presente invenção fornece o uso combinado de derivados de distamicina de acriloila substituidas, e particularmente <244>-bromo- e <244>-cloro-distamicina acriloila da fórmula (1), como especificado no relatório, e um anticorpo inibidor do fator de crescimento ou seu receptor, no tratamento de tumores. Também é fornecido o uso das ditas combinações no tratamento ou na prevenção da metástase ou no tratamento de tumores pela inibição da angiogênese.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05102792 | 2005-04-08 | ||
| PCT/EP2006/061153 WO2006108763A1 (en) | 2005-04-08 | 2006-03-29 | Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0607499A2 true BRPI0607499A2 (pt) | 2009-06-13 |
Family
ID=36624474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0607499-5A BRPI0607499A2 (pt) | 2005-04-08 | 2006-03-29 | combinação antitumor que compreende derivados de distamicina acriloìla substituìda e anticorpos que inibem fatores de crescimento ou seus receptores |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20090074757A1 (pt) |
| EP (1) | EP1868599B1 (pt) |
| JP (1) | JP2008534649A (pt) |
| CN (1) | CN101141955A (pt) |
| AT (1) | ATE447950T1 (pt) |
| AU (1) | AU2006233856A1 (pt) |
| BR (1) | BRPI0607499A2 (pt) |
| CA (1) | CA2598578A1 (pt) |
| CY (1) | CY1109782T1 (pt) |
| DE (1) | DE602006010349D1 (pt) |
| DK (1) | DK1868599T3 (pt) |
| EA (1) | EA011574B1 (pt) |
| ES (1) | ES2335805T3 (pt) |
| HR (1) | HRP20090617T1 (pt) |
| MX (1) | MX2007010525A (pt) |
| PL (1) | PL1868599T3 (pt) |
| PT (1) | PT1868599E (pt) |
| RS (1) | RS51231B (pt) |
| SI (1) | SI1868599T1 (pt) |
| WO (1) | WO2006108763A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2868791A1 (en) * | 2012-03-30 | 2013-10-03 | The Regents Of The University Of California | Anti-emp2 therapy reduces cancer stem cells |
| US10385395B2 (en) | 2012-04-11 | 2019-08-20 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
| CN109966499A (zh) * | 2019-04-25 | 2019-07-05 | 苏州大学 | 协同增效的抗乳腺癌转移药物组合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5165922A (en) * | 1990-05-22 | 1992-11-24 | Bristol-Myers Squibb Company | Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy |
| US6150508A (en) * | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| DE60210329T2 (de) * | 2002-01-02 | 2006-11-30 | Nerviano Medical Sciences S.R.L., Nerviano | Kombinierte tumortherapie auf der basis von substituierten acryloyl-distamycin-derivaten und protein-kinase (serin/threonin-kinase) inhibitoren |
| PL373998A1 (en) * | 2002-04-02 | 2005-09-19 | Pharmacia Italia Spa | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy |
-
2006
- 2006-03-29 AT AT06725409T patent/ATE447950T1/de active
- 2006-03-29 CA CA002598578A patent/CA2598578A1/en not_active Abandoned
- 2006-03-29 DE DE602006010349T patent/DE602006010349D1/de not_active Expired - Lifetime
- 2006-03-29 EA EA200702197A patent/EA011574B1/ru not_active IP Right Cessation
- 2006-03-29 CN CNA2006800088834A patent/CN101141955A/zh active Pending
- 2006-03-29 HR HR20090617T patent/HRP20090617T1/hr unknown
- 2006-03-29 US US11/887,998 patent/US20090074757A1/en not_active Abandoned
- 2006-03-29 EP EP06725409A patent/EP1868599B1/en not_active Expired - Lifetime
- 2006-03-29 JP JP2008504744A patent/JP2008534649A/ja not_active Withdrawn
- 2006-03-29 SI SI200630513T patent/SI1868599T1/sl unknown
- 2006-03-29 PT PT06725409T patent/PT1868599E/pt unknown
- 2006-03-29 MX MX2007010525A patent/MX2007010525A/es active IP Right Grant
- 2006-03-29 DK DK06725409.4T patent/DK1868599T3/da active
- 2006-03-29 BR BRPI0607499-5A patent/BRPI0607499A2/pt not_active IP Right Cessation
- 2006-03-29 WO PCT/EP2006/061153 patent/WO2006108763A1/en not_active Ceased
- 2006-03-29 RS RSP-2010/0007A patent/RS51231B/sr unknown
- 2006-03-29 PL PL06725409T patent/PL1868599T3/pl unknown
- 2006-03-29 ES ES06725409T patent/ES2335805T3/es not_active Expired - Lifetime
- 2006-03-29 AU AU2006233856A patent/AU2006233856A1/en not_active Abandoned
-
2010
- 2010-02-11 CY CY20101100141T patent/CY1109782T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2335805T3 (es) | 2010-04-05 |
| PT1868599E (pt) | 2010-01-26 |
| PL1868599T3 (pl) | 2010-04-30 |
| ATE447950T1 (de) | 2009-11-15 |
| DK1868599T3 (da) | 2010-02-15 |
| CN101141955A (zh) | 2008-03-12 |
| CA2598578A1 (en) | 2006-10-19 |
| AU2006233856A1 (en) | 2006-10-19 |
| SI1868599T1 (sl) | 2010-01-29 |
| EP1868599B1 (en) | 2009-11-11 |
| DE602006010349D1 (de) | 2009-12-24 |
| RS51231B (sr) | 2010-12-31 |
| JP2008534649A (ja) | 2008-08-28 |
| US20090074757A1 (en) | 2009-03-19 |
| MX2007010525A (es) | 2008-01-16 |
| WO2006108763A1 (en) | 2006-10-19 |
| HRP20090617T1 (hr) | 2009-12-31 |
| EA011574B1 (ru) | 2009-04-28 |
| EA200702197A1 (ru) | 2008-02-28 |
| EP1868599A1 (en) | 2007-12-26 |
| CY1109782T1 (el) | 2014-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE499097T1 (de) | Monozyklische heterozyklen als kinase-hemmer | |
| TR201011157T1 (tr) | Diglisidik eter türevi terapotikleri ve bunların kullanılma yöntemleri. | |
| MY155621A (en) | Axl antibodies | |
| EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
| ATE527253T1 (de) | Pyrimidin-substituierte benzimidazolderivate als proteinkinasehemmer | |
| NO20090624L (no) | Forbindelser som modulerer CB2 receptoren | |
| SG163585A1 (en) | Melanocortin receptor ligands | |
| PH12015500248A1 (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| EA200801428A1 (ru) | Производные пиридиазинона для лечения опухолей | |
| DK1761520T3 (da) | Kinaseinhibitorer | |
| EA201000558A1 (ru) | Производные имидазола | |
| EA200701853A1 (ru) | Производные циклопентапиридина и тетрагидрохинолина | |
| CR11126A (es) | Inhibicion de metastasis de tumor por anticuerpos anti neuropilina 2 | |
| EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
| TW200624426A (en) | BACE inhibitors | |
| UA85505C2 (en) | Kinase inhibitors | |
| UA85087C2 (en) | Monocyclic heterocycles as kinase inhibitors | |
| CY1109782T1 (el) | Αντικαρκινικος συνδυασμος που περιλαμβανει παραγωγα υποκατεστημενης ακρυλοϋλικης δισταμυκινης και αντισωματα που αναστελλουν αυξητικους παραγοντες ή τους υποδοχεις τους | |
| DE602006021327D1 (de) | Isochinoline als igf-1r-inhibitoren | |
| WO2007033140A3 (en) | Prok2 antagonists and methods of use | |
| ATE443053T1 (de) | Als inhibitoren von erbb-tyrosinkinase verwendete chinazoleinderivate | |
| TW200602023A (en) | Monocyclic heterocycles as kinase inhibitors | |
| GT200600016A (es) | Compuestos farmaceuticos | |
| ATE540951T1 (de) | Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren | |
| TW200730499A (en) | Targeting GLI proteins in human cancer by small molecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |